Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sotera Health CoSHC +0.73%77 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus rates SHC with a GF Score™ of 77/100 and a GF Value™ of $16.40 (Fairly Valued). The stock has 4 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, Sotera Health Co ranks worse than 598801.8% on this metric.
During the past 12 months, Sotera Health Co's average EBITDA Per Share Growth Rate was 14.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sotera Health Co was 4.00% per year. The lowest was 2.20% per year. And the median was 2.60% per year.
Sotera Health Co (NAS:SHC) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Sotera Health Co 3-Year EBITDA Growth Rate Related Terms
SHC vs RDNT, VCYT, TWST: 3-Year EBITDA Growth Rate Comparison
For the Diagnostics & Research subindustry, Sotera Health Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotera Health Co 3-Year EBITDA Growth Rate vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Sotera Health Co's 3-Year EBITDA Growth Rate falls into.
Sotera Health Co 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Sotera Health Co (SHC) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sotera Health Co and its competitors. Over the past decade, Sotera Health Co's 3-Year EBITDA Growth Rate has ranged from 2.20 to 4.00. According to the industry distribution chart, Sotera Health Co ranks #999999 out of 167 companies in the Medical Diagnostics & Research industry.
Is Sotera Health Co's 3-Year EBITDA Growth Rate too high?
Sotera Health Co's current 3-Year EBITDA Growth Rate is 0.00%. Over the past 10 years, this metric has ranged from a low of 2.20 to a high of 4.00. Based on the distribution chart, Sotera Health Co ranks #999999 out of 167 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Sotera Health Co has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sotera Health Co's 3-Year EBITDA Growth Rate compare to RDNT and VCYT?
According to the Medical Diagnostics & Research industry distribution chart, Sotera Health Co ranks #999999 out of 167 companies for 3-Year EBITDA Growth Rate. This places Sotera Health Co in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 11.00. Historically, Sotera Health Co's own 3-Year EBITDA Growth Rate has ranged from 2.20 to 4.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Diagnostics & Research company?
The median 3-Year EBITDA Growth Rate among Medical Diagnostics & Research companies is 11.00, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sotera Health Co and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year EBITDA Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotera Health Co's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotera Health Co stock overvalued right now?
Based on GuruFocus' analysis, Sotera Health Co (SHC) is currently considered Fairly Valued. The stock's GF Value™ is $16.40, compared to a current price of $17.99 — trading 9.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Sotera Health Co's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Sotera Health Co (SHC), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotera Health Co (SHC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued.
The current stock price of $17.99 is trading 9.7% above its estimated GF Value™ of $16.40.
GuruFocus considers Sotera Health Co to be Fairly Valued.
Key valuation signals for SHC:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: $16.40 vs. price of $17.99 (9.7% above fair value)
No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
77GF Score
Get the complete analysis for SHC
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHC has been successfully added to your 
